Fortunately for Mesoblast they now how the data from several trials, including numerous phase 3 trials, describing reasonable MOA. So much so we have 1 imminent BLA application, 2 more very tailored phase 3 trials on their way, and a the very real potential for CHF approval in some form. At worst, 3 tailored phase 3 trials, and still the imminent BLA.
And judging from existing trial data, and not arbitrarily relating it to the Novartis's decision, we know the cells work. NIH is still in for COVID.
They obviously see something there even if the resident absurdists don't see it, or decide to willfully ignore it. The only way they can argue against the potential of this stock is to make ridiculously absurd arguments that do not have a logical end.
Lets leave here with this :
"My focus is on deliverables, on approvals, on products in the marketplace, and revenues. That's really what I focus most of my time on, and the vagaries of the market will look after themselves when we deliver and as we deliver. And I firmly believe that. " - SI a few days ago.
2022 ... Get your popcorn out!, page-7
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.020(1.73%) |
Mkt cap ! $1.341B | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.21 | $1.17 | $16.67M | 14.04M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 54704 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.19 |
Change
0.020 ( 3.40 %) |
||||
| Open | High | Low | Volume | ||
| $1.21 | $1.21 | $1.17 | 2927691 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| MSB (ASX) Chart |